HC Wainwright Issues Positive Forecast for Kyverna Therapeutics (NASDAQ:KYTX) Stock Price

Kyverna Therapeutics (NASDAQ:KYTX) had its price objective raised by HC Wainwright from $20.00 to $25.00 in a research report report published on Friday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. JPMorgan Chase & Co. lowered their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Kyverna Therapeutics Price Performance

Shares of KYTX stock opened at $9.49 on Friday. Kyverna Therapeutics has a twelve month low of $2.06 and a twelve month high of $13.67. The stock has a market capitalization of $576.90 million, a price-to-earnings ratio of -2.89 and a beta of 2.05. The stock has a fifty day simple moving average of $9.05 and a two-hundred day simple moving average of $8.38. The company has a current ratio of 8.15, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. On average, analysts predict that Kyverna Therapeutics will post -2.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KYTX. Bank of America Corp DE raised its position in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after buying an additional 16,267 shares in the last quarter. AQR Capital Management LLC acquired a new position in Kyverna Therapeutics during the 1st quarter valued at about $137,000. Rhumbline Advisers increased its position in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after buying an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Kyverna Therapeutics during the 2nd quarter valued at about $107,000. 18.08% of the stock is owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.